How do you pay?

How to pay the least

Ask for the cash price

Sunlenca

We didn’t find one.

  1. Ask your pharmacy for Sunlenca’s cash price, and one or two other pharmacies too.
  2. Sunlenca’s savings card works only with insurance from a job or one you bought.

Free from the maker, if you qualify Advancing Access Patient Assistance Program/Medication Assistance Program (PAP/MAP). Or call 1-800-226-2056.

See if you qualify 

Compare every option

Question
Brand nameSunlenca
Authorized genericlenacapavir
Regular genericlenacapavir
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Sunlenca?
The original
–
–

Brand nameThe maker’s card

Gilead Advancing Access Co-pay Savings Program

Savings card from Gilead Sciences

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a fill

Sign up on sunlenca.com 

Or call 1-800-226-2056.

In the maker’s words

“If you are eligible, Advancing Access may be able to help you lower your co-pay to as little as $0.”

From the maker’s offer on sunlenca.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Sunlenca itself, from the same company, sold without the brand name, and usually for less. For now Sunlenca is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

SUNLENCA, a human immunodeficiency virus type 1 (HIV-1) capsid inhibitor, is indicated:

  • in combination with other antiretroviral(s), for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug resistant HIV-1 whose current antiretroviral regimen is failing due to resistance, intolerance, or safety considerations.
  • for oral loading as a component of the initiation regimen for BIXLENVO (bictegravir [BIC]/lenacapavir [LEN]), a complete regimen for the treatment of HIV-1 infection, in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no known or suspected resistance to the individual components of BIXLENVO.

Source: the FDA label for Sunlenca (Gilead Sciences, Inc.), August 27, 2026. Full label on DailyMed 

Good to know